Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival.
Rudolf Arnold
Honoraria - Novartis
Michael Wittenberg
No relevant relationships to disclose
Anja Rinke
Consultant or Advisory Role - Ipsen; Novartis
Honoraria - Ipsen; Novartis; Pfizer
Carmen Schade-Brittinger
No relevant relationships to disclose
Behnaz Aminossadati
No relevant relationships to disclose
Erdmuthe Ronicke
No relevant relationships to disclose
Thomas Mathias Gress
Honoraria - Novartis
Research Funding - Novartis
Hans Helge Mueller
No relevant relationships to disclose